Alteration of thioredoxin reductase 1 levels in elucidating cancer etiology.
Thioredoxin reductase 1 (TR1) is a major antioxidant and redox regulator in mammalian cells and appears to function as a double-edged sword in that it has roles in preventing and promoting/sustaining cancer. TR1 is overexpressed in many cancer cells and targeting its removal often leads to a reversal in numerous malignant characteristics which has marked this selenoenzyme as a prime target for cancer therapy. Since alterations in TR1 activity may lead to a better understanding of the etiology of cancer and new avenues for providing better therapeutic procedures, we have described herein techniques for removing and reexpressing TR1 employing RNAi technology and for assessing the catalytic activity of this enzyme.
Yoo
Min-Hyuk
MH
Molecular Biology of Selenium Section, Laboratory of Cancer Prevention, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Carlson
Bradley A
BA
Tsuji
Petra
P
Irons
Robert
R
Gladyshev
Vadim N
VN
Hatfield
Dolph L
DL
D000818:Animals; D015152:Blotting, Northern; D015153:Blotting, Western; D045744:Cell Line, Tumor; D055785:Gene Knockdown Techniques; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000201:enzymology* / Q000209:etiology / Q000235:genetics; D013880:Thioredoxin-Disulfide Reductase / Q000032:analysis / Q000235:genetics / Q000378:metabolism*
D013880:Thioredoxin-Disulfide Reductase